We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Campaigners in the US and Malta are protesting against laws that prevent doctors inducing abortion even in dangerous circumstances
Owning physical drugstores is not the cash cow it once was
Remote providers report a leap in requests as conservative US states roll out a number of restrictions
Short break in immune suppression treatment improves antibody production after vaccination while doing little harm
UK social care provider has benefited from rising demand during the pandemic
Javid says he asked officials to revise previous plans that would exclude under-65s
US prepares to roll out jabs to last age group without access once regulatory approval is received
The ‘testimonials’ page of many facilities is long on statements from relatives, but not from those in care themselves
Charities warn trend could lead to ‘vicious cycle’ barring many aged 18-24 from workforce
Private hospitals group says offer from shipping group and its biggest shareholder undervalues company
Protein-based vaccine is an alternative to mRNA technology used by BioNTech/Pfizer and Moderna
The NHS needs long-term investment to build capacity and a shift in the balance away from hospital treatment
Nurses were lauded as ‘heroes’ by governments when the pandemic hit, but dismal working conditions have led many to quit the profession
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Prevention is better than cure — but is too costly for some countries where drug-resistant bacteria are rampant
Identifying conditions can prevent inappropriate drug use, but there are barriers to progress in poorer regions
Healthcare litigation group MSP Recovery had claimed a $33bn valuation despite losses
People with a history of autoimmune disease or depression were also more likely to have the condition
Officials are reacting to the largest outbreak outside sub-Saharan Africa
Health service problems stemming from political choices are not an argument for a radical overhaul
Public debate has been riddled with confusing claims, technical incompetence and vested interests
Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting
Underfunding of some services and pent-up demand caused by lockdowns means some young people are waiting months for help
The creeping Americanisation of British medical bills reflects the strains on the NHS
The final instalment of our series on innovation in European healthcare examines the effects of the slump in biotech valuations and changes in EU health policy
International Edition
